<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 22, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442284</url>
  </required_header>
  <id_info>
    <org_study_id>M14-251</org_study_id>
    <nct_id>NCT02442284</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety and efficacy of Ombitasvir/Paritaprevir/Ritonavir and
      Dasabuvir with or without Ribavirin in US veterans with genotype 1 chronic hepatitis C virus
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic failure during treatment</measure>
    <time_frame>Up to 24 weeks while on treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with confirmed, quantifiable HCV RNA levels among participants with previous unquantifiable HCV RNA during treatment and participants who did not achieve unquantifiable HCV RNA at end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic relapse post-treatment</measure>
    <time_frame>Up to 24 weeks after last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of participants with confirmed, quantifiable HCV RNA levels among participants with previous unquantifiable HCV RNA at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Sustained Virologic Response 12 weeks post-treatment among participants with ongoing psychiatric disorders</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than the lower limit of quantification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Cirrhosis</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>OBV/PTV/r and DSV with/without RBV for 12 or 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ombitasvir(OBV)/paritaprevir(PTV)/ritonavir(r) and dasabuvir(DSV) with or without Ribavirin (RBV) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir</intervention_name>
    <arm_group_label>OBV/PTV/r and DSV with/without RBV for 12 or 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paritaprevir</intervention_name>
    <arm_group_label>OBV/PTV/r and DSV with/without RBV for 12 or 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>OBV/PTV/r and DSV with/without RBV for 12 or 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <arm_group_label>OBV/PTV/r and DSV with/without RBV for 12 or 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>OBV/PTV/r and DSV with/without RBV for 12 or 24 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. US military veteran currently receiving healthcare through the Veterans Health
             Administration

          2. Screening laboratory result indicating HCV, genotype 1-infection

          3. Positive for hepatitis C antibodies or HCV RNA at least 6 months before Screening,
             and HCV RNA &gt; 1,000 IU/mL at the time of Screening or HCV RNA &gt; 1,000 IU/mL at the
             time of Screening with a liver biopsy consistent with chronic HCV-infection (or a
             liver biopsy performed prior to enrollment with evidence of chronic hepatitis C
             disease)

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding

          2. Positive test result for hepatitis B surface antigen (HbsAg) or anti-HIV antibodies
             (HIV Ab)

          3. Prior or current use of any investigational or commercially available anti-HCV agents
             other than IFN, pegIFN, RBV or sofosbuvir

          4. Any current or past clinical evidence of Child-Pugh B or C classification

          5. Confirmed presence of hepatocellular carcinoma indicated on imaging techniques within
             3 months prior to Screening or on an ultrasound performed at Screening for
             participants with cirrhosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariem Charafeddine, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Knapik, MS</last_name>
    <phone>816-524-0542</phone>
    <email>julie.knapik@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tori Mullally, MS</last_name>
    <phone>847-935-1406</phone>
    <email>tori.mullally@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136287</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136287, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136289</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136289</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136236</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136236, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137224</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137224, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136232</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136232, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136295</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136295</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136290</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136290</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136235</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136235, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136234</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136234, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136294</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136294</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136849</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 136849, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 23, 2015</lastchanged_date>
  <firstreceived_date>May 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Interferon-Free</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Cirrhosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
